O. V. Ionov

O. V. Ionov

Auto-generated profile, based on publicly available information

O. V. Ionov

National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov, Ministry of Health of the Russian Federation, Moscow

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Journal of Chromatography B
Verified
Journal Article
Closed access
Alexey S. KononikhinAlexey S. Kononikhin
Alexey S. Kononikhin
NSNatalia Starodubtseva
Natalia Starodubtseva
VCVitaliy V. Chagovets
Vitaliy V. Chagovets
ARA.Y. Ryndin
A.Y. Ryndin
ABArtem Burov
Artem Burov
GSG.T. Sukhikh
G.T. Sukhikh

1 January 2022 in Neonatology: News, Opinions, Training
Verified
Journal Article
Closed access
ARA.A. Rudakova
A.A. Rudakova
OIO.V. Ionov
O.V. Ionov
EFE.A. Filippova
E.A. Filippova
ASA.B. Sugak
A.B. Sugak
AKA.R. Kirtbaya
A.R. Kirtbaya
MFMoscow Russian Medical Academy Of Continuous Professional Education Of The Ministry Of Healthcare Of The Russian Federation
Moscow Russian Medical Academy Of Continuous Professional Education Of The Ministry Of Healthcare Of The Russian Federation
Возможности и ограничения применения эхокардиографии врачом интенсивной терапии в отделении реанимации и интенсивной терапии новорожденных

1 January 2022 in Neonatology: News, Opinions, Training
Verified
Journal Article
Closed access
AKA.R. Kirtbaya
A.R. Kirtbaya
VLV.M. Lyapin
V.M. Lyapin
AYA.A. Yepiphantceva
A.A. Yepiphantceva
ASA.I. Shchegolev
A.I. Shchegolev
EBE.N. Balashova
E.N. Balashova
DDD.N. Degtyarev
D.N. Degtyarev

1 January 2023 in Neonatology: News, Opinions, Training
Verified
Journal Article
Closed access
OIO.V. Ionov
O.V. Ionov
DSD.R. Sharafutdinova
D.R. Sharafutdinova
EBE.N. Balashova
E.N. Balashova
AKA.R. Kirtbaya
A.R. Kirtbaya
EKE.E. Kosterina
E.E. Kosterina
DDD.N. Degtyarev
D.N. Degtyarev
Факторы, ассоциированные с развитием некротизирующего энтероколита у новорожденных с экстремально низкой массой тела при рождении: ретроспективный

1 January 2023 in Neonatology: News, Opinions, Training
Verified
Journal Article
Open access
EBE.N. Balashova
E.N. Balashova
VVV.V. Vasil’ev
V.V. Vasil’ev
NVN.P. Vaynshteyn
N.P. Vaynshteyn
MDM.V. Degtyareva
M.V. Degtyareva
VZV.V. Zubkov
V.V. Zubkov
SKSt. Petersburg Military Medical Academy Named After S.M. Kirov
St. Petersburg Military Medical Academy Named After S.M. Kirov
Врожденная цитомегаловирусная инфекция (клинические рекомендации)

29 June 2019 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
DSD. R. Sharafutdinova
D. R. Sharafutdinova
EBE. N. Balashova
E. N. Balashova
OIO. V. Ionov
O. V. Ionov
AKA. R. Kirtbaya
A. R. Kirtbaya
JGJ. M. Golubtsova
J. M. Golubtsova
SPS. V. Pavlovich
S. V. Pavlovich
Anemia of prematurity is a common pathology in premature infants. The prevalence of anemia of prematurity is inversely proportional to the gestational age and body weight at birth. The pathogenetic importance of impaired erythropoietin (EPO) production in anemia of prematurity provides the rationale for therapy with erythropoiesis stimulating agents (ESAs) including recombinant EPO. A comparative analysis of the effectiveness of different regimens of recombinant human erythropoietin in extremely and very low birth weight infants (ELBW and VLBW) was studied. Research has been set as a prospective analysis of 133 VLBW and ELBW infants (in the period from December 2017 to February 2019). Gestational age (GA) of the children ranged from 26 to 33 weeks, of these, GA of 75 children (56%) was 30 weeks or less. Depending on the treatment of anemia of prematurity all infants were divided into 5 groups: group 1 (n = 26) – premature babies who were prescribed ESAs since 3 day of life 200 IU/kg 3 times per week subcutaneously; group 2 (n = 21) – premature babies who were prescribed ESAs since 3 day of life 400 IU/kg 3 times per week subcutaneously; group 3 (n = 37) – premature babies who were prescribed ESAs since 8 day of life 200 IU/kg 3 times per week subcutaneously; group 4 (n = 18) – premature babies who were prescribed ESAs since 8 day of life 400 IU/kg 3 times per week subcutaneously; group 5 (n = 31) premature infants who did not receive treatment with recombinant human erythropoietin (control group). Subgroups of children of gestational age ≤ 30 weeks were identified in each group. The groups and subgroups did not differ significantly in gestational age, weight, birth length, and Apgar score at 1 and 5 minutes of life, p 0.05. Also, there were no statistically significant differences in the age of the 1st transfusion, the frequency and total volume of transfusions, the duration of respiratory therapy, the duration of hospitalization, including treatment in NICU, body weight and age at discharge. The frequency of retinopathy of prematurity stage ≥ 3, periventricular leukomalacia, bronchopulmonary dysplasia of moderate and severe severity, intraventricular hemorrhages of varying severity, necrotizing enterocolitis was not statistically significant in the study groups and subgroups. Statistically significant differences in the concentration of hemoglobin in the peripheral blood of premature infants were revealed at discharge. In the control group, children had a lower level of hemoglobin at discharge (94 g/l) compared with the groups with early appointment of ESAs (109 g/l and 107 g/l in groups 1 and 2, respectively, P0-1 = 0.048 and P0-2 = 0.047) due to newborn GA ≤ 30 weeks. It is preferable to use of the drug ESAs at a dose of 200 IU/kg 3 p/week p/, starting from the 3rd day of life. The effectiveness of erythropoietin therapy, the time of its start and various treatment regimens remain controversial issues that require further study. The study was approved by the Independent Ethics Committee of the National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov.